Highest-materiality recent filing
Neuphoria receives AUD 1.416M CTx CRC payment; eligible for ~4.65% of $460M milestones
Received AUD 1.416M from CTx CRC upon Pfizer's Phase III start in ER+/HER2- metastatic breast cancer.
CEO Spyridon Papapetropoulos transitions to interim CEO under consulting agreement
Employment terminated Dec 31, 2025; Papapetropoulos remains on Board of Directors.
Neuphoria Therapeutics regains Nasdaq compliance after holding 2025 annual meeting
Received Nasdaq deficiency notice on July 18, 2025 for failing to hold annual meeting within 12 months of FY end (Rule 5620(a)).
Neuphoria Therapeutics Announces Annual Meeting Voting Results; Elects Two Class I Directors
Shareholders elected Peter Miles Davies (759,850 votes for) and David Wilson (758,571) as Class I directors.
Neuphoria adopts poison pill after investor accumulates >20%; launches strategic review
Rights plan triggered if any entity acquires 15%+ beneficial ownership without board approval.
AFFIRM-1 Phase 3 trial did not meet primary endpoint of change in SUDS scores during speech challenge; secondary endpoints also not significant.
Nasdaq grants Neuphoria 180-day extension to hold annual meeting, cure listing deficiency
Nasdaq accepted compliance plan on Sept 10, 2025; new deadline Dec 29, 2025.
Neuphoria receives Nasdaq deficiency notice for missing annual meeting; plans compliance plan
Received Nasdaq notice on July 18, 2025 for failure to hold annual meeting within 12 months of fiscal year ended June 30, 2024.
Neuphoria Q1 update: BNC-210 Phase 3 topline due Q3 2025; cash runway into Q3 2026
Cash runway extends into Q3 2026; no near-term financing risk stated.
Neuphoria Therapeutics regains Nasdaq minimum bid price compliance
Received Nasdaq letter confirming compliance with Minimum Bid Price Rule 5450(a)(1) on Jan 10, 2025.
Neuphoria completes redomiciliation from Australia to Delaware; shares to trade under NEUP
Effective Dec 23, 2024, Bionomics Ltd. became a wholly-owned subsidiary of Neuphoria; NEUP shares to trade on Nasdaq from Dec 24.
Court approves Bionomics' re-domiciliation; Neuphoria to list Dec 24 under NEUP
Supreme Court of NSW approved Scheme of Arrangement on Dec 16, 2024; scheme became legally effective after lodgment with ASIC.
Bionomics shareholders approve re-domiciliation to U.S. via Neuphoria; 96% vote in favor
96% of votes cast and 87% of shareholders present voted in favor of scheme to re-domicile from Australia to Delaware.
Bionomics enters $2M ATM offering with H.C. Wainwright, replaces prior $11.5M program
Signed ATM agreement with H.C. Wainwright for up to $2 million in ADSs; 3.0% sales commission.
Bionomics announces amended exchange ratio for re-domicile merger; court approves Dec 12 meeting
Amended exchange ratio: 1 Neuphoria share per 2,160 Bionomics ordinary shares; 1 per 12 ADSs.
Bionomics director Aaron Weaver resigns from board effective Oct 9, 2024
Aaron Weaver resigned from Bionomics' Board of Directors on October 9, 2024.
Bionomics to re-domicile from Australia to US via scheme of arrangement with Neuphoria
Holders receive 1 Neuphoria share per 1,440 ordinary shares or per 8 ADSs; estimated post-domicile Nasdaq price ~$3.50.
Bionomics receives Nasdaq bid price deficiency notice; has until Jan 7, 2025 to regain compliance
Nasdaq notified Bionomics on July 11, 2024 that its ADS bid price closed below $1.00 for 30 consecutive business days.
On October 9, 2024, Mr. Aaron Weaver, a member of the Board of Directors of Bionomics Limited (the “Company”), provided the Company’s board with notice that he was resigning from the Board of Directors, effective October 9, 2024.
Max materiality 0.90 · Median 0.60 · Most common event other_material